Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (396 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.46, 5-year impact factor: 2.349
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84904538729&partnerID=40&md5=6d5acc50c0de3c6c85a7099c9056cf1d
Keywords: Low Degree Bone Pain, Palliation, Radionuclide Therapy, Sm-153 Edtmp, Analgesic Agent, Antineoplastic Agent, Etidronic Acid Tc 99m, Lexidronam Samarium Sm 153, Nonsteroid Antiinflammatory Agent, Zoledronic Acid, Adult, Article, Bleeding, Blood Toxicity, Bone Marrow Suppression, Bone Metastasis, Bone Scintiscanning, Breast Cancer, Cancer Chemotherapy, Cancer Hormone Therapy, Cancer Palliative Therapy, Cancer Patient, Cancer Radiotherapy, Clinical Article, Clinical Evaluation, Controlled Study, Drug Efficacy, Drug Safety, Female, Human, Infection, Lung Cancer, Multimodality Cancer Therapy, Pain Assessment, Physician, Priority Journal, Radioisotope Therapy, Risk Reduction, Treatment Duration, Treatment Outcome, Treatment Response, Visual Analog Scale, 80 And Over, Bone Neoplasms Radiotherapy, Middle Aged, Pain Radiotherapy, Palliative Care Methods, Samarium Therapeutic Use, Procedures, Very Elderly,
Affiliations:
*** IBB - CNR ***
Istituto di Ricovero e Cura Carattere Scientifico, Centro di Riferimento Oncologico di Basilicata, via P. Pio 1, 85028 Rionero in Vulture, Italy
Institute of Biostructure and Bioimages, National Council of Research, Naples, Italy
University of Texas Southwestern, Dallas, TX, United States
References:
Reddi, A. H., Roodman, D., Freeman, C., Mohla, S., Mechanisms of tumor metastasis to the bone: Challenges and opportunities (2003) J Bone Miner Res, 18, pp. 190-194
Nielsen, O. S., Munro, A. J., Tannock, I. F., Bone metastases: Pathophysiology and management policy (1991) J Clin Oncol, 9, pp. 509-524
Coleman, R. E., Rubens, R. D., The clinical course of bone metastases from breast cancer (1987) British Journal of Cancer, 55 (1), pp. 61-66
Keller, E. T., Brown, J., Prostate cancer bone metastases promote both osteolytic and osteoblastic activity (2004) J Cell Biol, 91, pp. 718-729
Hortobagyi, G. N., Novel approaches to the management of bone metastases in patients with breast cancer (2002) Semin Oncol, 29, pp. 134-144
Burris III, H. A., Lebrun, F., Rugo, H. S., Beck, J. T., Piccart, M., Neven, P., Baselga, J., Noguchi, S., Healthrelated quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial (2013) Cancer, 119, pp. 1908-1915
Perry, C. M., Figgitt, D. P., Zoledronic acid: A review of its use in patients with advanced cancer (2004) Drugs, 64 (11), pp. 1197-1211. , DOI 10. 2165/00003495-200464110-00004
Soloway, M. S., Ishikawa, S., Van Der, Z. R., Todd, B., Prognostic factors in patients with advanced prostate cancer (1989) Urology, 33 (5 SUPPL.), pp. 53-56. , DOI 10. 1016/0090-4295 (89) 90107-6
Kassamali, R. H., Ganeshan, A., Hoey, E. T., Crowe, P. M., Douis, H., Henderson, J., Pain management in spinal metastases: The role of percutaneous vertebral augmentation (2011) Ann Oncol, 22, pp. 782-786
Body, J. J., Bone metastases and tumor-induced hypercalcaemia (1992) Curr Opin Oncol, 4, pp. 624-631
Resche, I., Chatal, J. -F., Pecking, A., Ell, P., Duchesne, G., Rubens, R., Fogelman, I., Wilkins, D., A dose-controlled study of 153Sm- ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases (1997) European Journal of Cancer, 33 (10), pp. 1583-1591. , DOI 10. 1016/S0959-8049 (97) 00155-X, PII S095980499700155X
Sartor, O., Reid, R. H., Hoskin, P. J., Quick, D. P., Ell, P. J., Coleman, R. E., Kotler, J. A., Olivier, P., Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer (2004) Urology, 63 (5), pp. 940-945. , DOI 10. 1016/j. urology. 2004. 01. 034, PII S0090429504001438
Serafini, A. N., Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastasis (2000) Cancer, 88, pp. 2934-2939
Serafini, A. N., Houston, S. J., Resche, I., Quick, D. P., Grund, F. M., Ell, P. J., Bertrand, A., Harrison, K. A., Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial (1998) Journal of Clinical Oncology, 16 (4), pp. 1574-1581
Sciuto, R., Maini, C. L., Tofani, A., Fiumara, C., Scelsa, M. G., Broccatelli, M., Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89 (1996) Nuclear Medicine Communications, 17 (9), pp. 799-804
Ron, I. -G., Stav, O., Vishne, T., Evan-Sapir, E., Soyfer, V., Agai, R., Cherny, N., Kovner, F., The correlation between palliation of bone pain by intravenous strontium-89 and external beam radiation to linked field in patients with osteoblastic bone metastases (2004) American Journal of Clinical Oncology: Cancer Clinical Trials, 27 (5), pp. 500-504. , DOI 10. 1097/01. coc. 0000135378. 67644. ba
Sciuto, R., Festa, A., Rea, S., Pasqualoni, R., Bergomi, S., Petrilli, G., Maini, C. L., Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial (2002) Journal of Nuclear Medicine, 43 (1), pp. 79-86
Storto, G., Klain, M., Paone, G., Liuzzi, R., Molino, L., Marinelli, A., Soricelli, A., Salvatore, M., Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (2006) Bone, 39 (1), pp. 35-41. , DOI 10. 1016/j. bone. 2005. 12. 004, PII S8756328205005351
Hess, G., Barlev, A., Chung, K., Hill, J. W., Fonseca, E., Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer (2012) Radiat Oncol, 7, p. 168
Collins, C., Eary, J. F., Donaldson, G., Vernon, C., Bush, N. E., Petersdorf, S., Livingston, R. B., Appelbaum, F. R., Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial (1993) Journal of Nuclear Medicine, 34 (11), pp. 1839-1844
Pandit-Taskar, N., Batraki, M., Divgi, C. R., Radiopharmaceutical therapy for palliation of bone pain from osseous metastases (2004) Journal of Nuclear Medicine, 45 (8), pp. 1358-1365. , http: //jnm. snmjournals. org/cgi/reprint/45/8/1358
Mincey, B. A., Perez, E. A., Advances in screening, diagnosis, and treatment of breast cancer (2004) Mayo Clinic Proceedings, 79 (6), pp. 810-816
Decroisette, C., Galerneau, L. M., Hominal, S., Chouaid, C., Epidemiology, management and cost of bone metastases from lung cancer (2013) Rev Mal Respir, 30, pp. 309-315
Zhang, H., Tian, M., Li, S., Liu, J., Tanada, S., Endo, K., Rhenium-188-HEDP Therapy for the Palliation of Pain Due to Osseous Metastases in Lung Cancer Patients (2003) Cancer Biotherapy and Radiopharmaceuticals, 18 (5), pp. 719-726
Reich, C. D., Advances in the treatment of bone metastases (2003) Clin J Oncol Nurs, 7, pp. 641-646
Coronado, M., Redondo, A., Coya, J., Espinosa, E., Couto, R. Ma., Zamora, P., Marin, M. D., Curto, L. M. M., Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease (2006) Clinical Nuclear Medicine, 31 (10), pp. 605-610. , DOI 10. 1097/01. rlu. 0000238304. 08812. c1, PII 0000307220061000000004
Serafini, A. N., Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis (2001) Q J Nucl Med, 45, pp. 91-99
Berger, M., Grignani, G., Giostra, A., Ferrari, S., Ferraresi, V., Tamburini, A., Cefalo, G., Fagioli, F., 153 samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients (2012) Ann Oncol, 23, pp. 1899-1905
Lewington, V. J., Bone-seeking radionuclides for therapy (2005) J Nucl Med, 46, pp. 38S-47S
Turner, J. H., Claringbold, P. G., A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate (1991) Eur J Cancer, 27, pp. 1085-1086
Storto, G., Gallicchio, R., Pellegrino, T., Nardelli, A., De Luca, S., Capacchione, D., Sirignano, C., Pace, L., Impact of 18F-Fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (2013) Nucl Med Biol, 40, pp. 518-523
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Bonomi, P., The functional assessment of cancer therapy scale: Development and validation of the general measure (1993) Journal of Clinical Oncology, 11 (3), pp. 570-579
Hwang, S. S., Chang, V. T., Kasimis, B., Dynamic cancer pain management outcomes: The relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time (2002) Journal of Pain and Symptom Management, 23 (3), pp. 190-200. , DOI 10. 1016/S0885-3924 (01) 00418-3, PII S0885392401004183
Storto, G., Radionuclide Therapy (2009) Bone Metastases: A Translational and Clinical Approach, 12, pp. 321-341. , Kardamakis D, Vassiliou V, Chow E (eds) Springer, Netherlands
Sartor, O., Overview of samarium Sm 153 lexidronam in the treatment of painful metastatic bone disease (2004) Rev Urol, 6, pp. S3-S12
Reddi, A.H., Roodman, D., Freeman, C., Mohla, S., Mechanisms of tumor metastasis to the bone: Challenges and opportunities (2003) J Bone Miner Res, 18, pp. 190-194
Nielsen, O.S., Munro, A.J., Tannock, I.F., Bone metastases: Pathophysiology and management policy (1991) J Clin Oncol, 9, pp. 509-524
Coleman, R.E., Rubens, R.D., The clinical course of bone metastases from breast cancer (1987) British Journal of Cancer, 55 (1), pp. 61-66
Keller, E.T., Brown, J., Prostate cancer bone metastases promote both osteolytic and osteoblastic activity (2004) J Cell Biol, 91, pp. 718-729
Hortobagyi, G.N., Novel approaches to the management of bone metastases in patients with breast cancer (2002) Semin Oncol, 29, pp. 134-144
Burris III, H.A., Lebrun, F., Rugo, H.S., Beck, J.T., Piccart, M., Neven, P., Baselga, J., Noguchi, S., Healthrelated quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial (2013) Cancer, 119, pp. 1908-1915
Perry, C.M., Figgitt, D.P., Zoledronic acid: A review of its use in patients with advanced cancer (2004) Drugs, 64 (11), pp. 1197-1211. , DOI 10.2165/00003495-200464110-00004
Soloway, M.S., Ishikawa, S., Van Der, Z.R., Todd, B., Prognostic factors in patients with advanced prostate cancer (1989) Urology, 33 (5 SUPPL.), pp. 53-56. , DOI 10.1016/0090-4295(89)90107-6
Kassamali, R.H., Ganeshan, A., Hoey, E.T., Crowe, P.M., Douis, H., Henderson, J., Pain management in spinal metastases: The role of percutaneous vertebral augmentation (2011) Ann Oncol, 22, pp. 782-786
Body, J.J., Bone metastases and tumor-induced hypercalcaemia (1992) Curr Opin Oncol, 4, pp. 624-631
Serafini, A.N., Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastasis (2000) Cancer, 88, pp. 2934-2939
Serafini, A.N., Houston, S.J., Resche, I., Quick, D.P., Grund, F.M., Ell, P.J., Bertrand, A., Harrison, K.A., Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial (1998) Journal of Clinical Oncology, 16 (4), pp. 1574-1581
Ron, I.-G., Stav, O., Vishne, T., Evan-Sapir, E., Soyfer, V., Agai, R., Cherny, N., Kovner, F., The correlation between palliation of bone pain by intravenous strontium-89 and external beam radiation to linked field in patients with osteoblastic bone metastases (2004) American Journal of Clinical Oncology: Cancer Clinical Trials, 27 (5), pp. 500-504. , DOI 10.1097/01.coc.0000135378.67644.ba
Mincey, B.A., Perez, E.A., Advances in screening, diagnosis, and treatment of breast cancer (2004) Mayo Clinic Proceedings, 79 (6), pp. 810-816
Reich, C.D., Advances in the treatment of bone metastases (2003) Clin J Oncol Nurs, 7, pp. 641-646
Serafini, A.N., Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis (2001) Q J Nucl Med, 45, pp. 91-99
Lewington, V.J., Bone-seeking radionuclides for therapy (2005) J Nucl Med, 46, pp. 38S-47S
Turner, J.H., Claringbold, P.G., A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate (1991) Eur J Cancer, 27, pp. 1085-1086
Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Bonomi, P., The functional assessment of cancer therapy scale: Development and validation of the general measure (1993) Journal of Clinical Oncology, 11 (3), pp. 570-579
Hwang, S.S., Chang, V.T., Kasimis, B., Dynamic cancer pain management outcomes: The relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time (2002) Journal of Pain and Symptom Management, 23 (3), pp. 190-200. , DOI 10.1016/S0885-3924(01)00418-3, PII S0885392401004183
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.46, 5-year impact factor: 2.349
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84904538729&partnerID=40&md5=6d5acc50c0de3c6c85a7099c9056cf1d
Keywords: Low Degree Bone Pain, Palliation, Radionuclide Therapy, Sm-153 Edtmp, Analgesic Agent, Antineoplastic Agent, Etidronic Acid Tc 99m, Lexidronam Samarium Sm 153, Nonsteroid Antiinflammatory Agent, Zoledronic Acid, Adult, Article, Bleeding, Blood Toxicity, Bone Marrow Suppression, Bone Metastasis, Bone Scintiscanning, Breast Cancer, Cancer Chemotherapy, Cancer Hormone Therapy, Cancer Palliative Therapy, Cancer Patient, Cancer Radiotherapy, Clinical Article, Clinical Evaluation, Controlled Study, Drug Efficacy, Drug Safety, Female, Human, Infection, Lung Cancer, Multimodality Cancer Therapy, Pain Assessment, Physician, Priority Journal, Radioisotope Therapy, Risk Reduction, Treatment Duration, Treatment Outcome, Treatment Response, Visual Analog Scale, 80 And Over, Bone Neoplasms Radiotherapy, Middle Aged, Pain Radiotherapy, Palliative Care Methods, Samarium Therapeutic Use, Procedures, Very Elderly,
Affiliations:
*** IBB - CNR ***
Istituto di Ricovero e Cura Carattere Scientifico, Centro di Riferimento Oncologico di Basilicata, via P. Pio 1, 85028 Rionero in Vulture, Italy
Institute of Biostructure and Bioimages, National Council of Research, Naples, Italy
University of Texas Southwestern, Dallas, TX, United States
References:
Reddi, A. H., Roodman, D., Freeman, C., Mohla, S., Mechanisms of tumor metastasis to the bone: Challenges and opportunities (2003) J Bone Miner Res, 18, pp. 190-194
Nielsen, O. S., Munro, A. J., Tannock, I. F., Bone metastases: Pathophysiology and management policy (1991) J Clin Oncol, 9, pp. 509-524
Coleman, R. E., Rubens, R. D., The clinical course of bone metastases from breast cancer (1987) British Journal of Cancer, 55 (1), pp. 61-66
Keller, E. T., Brown, J., Prostate cancer bone metastases promote both osteolytic and osteoblastic activity (2004) J Cell Biol, 91, pp. 718-729
Hortobagyi, G. N., Novel approaches to the management of bone metastases in patients with breast cancer (2002) Semin Oncol, 29, pp. 134-144
Burris III, H. A., Lebrun, F., Rugo, H. S., Beck, J. T., Piccart, M., Neven, P., Baselga, J., Noguchi, S., Healthrelated quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial (2013) Cancer, 119, pp. 1908-1915
Perry, C. M., Figgitt, D. P., Zoledronic acid: A review of its use in patients with advanced cancer (2004) Drugs, 64 (11), pp. 1197-1211. , DOI 10. 2165/00003495-200464110-00004
Soloway, M. S., Ishikawa, S., Van Der, Z. R., Todd, B., Prognostic factors in patients with advanced prostate cancer (1989) Urology, 33 (5 SUPPL.), pp. 53-56. , DOI 10. 1016/0090-4295 (89) 90107-6
Kassamali, R. H., Ganeshan, A., Hoey, E. T., Crowe, P. M., Douis, H., Henderson, J., Pain management in spinal metastases: The role of percutaneous vertebral augmentation (2011) Ann Oncol, 22, pp. 782-786
Body, J. J., Bone metastases and tumor-induced hypercalcaemia (1992) Curr Opin Oncol, 4, pp. 624-631
Resche, I., Chatal, J. -F., Pecking, A., Ell, P., Duchesne, G., Rubens, R., Fogelman, I., Wilkins, D., A dose-controlled study of 153Sm- ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases (1997) European Journal of Cancer, 33 (10), pp. 1583-1591. , DOI 10. 1016/S0959-8049 (97) 00155-X, PII S095980499700155X
Sartor, O., Reid, R. H., Hoskin, P. J., Quick, D. P., Ell, P. J., Coleman, R. E., Kotler, J. A., Olivier, P., Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer (2004) Urology, 63 (5), pp. 940-945. , DOI 10. 1016/j. urology. 2004. 01. 034, PII S0090429504001438
Serafini, A. N., Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastasis (2000) Cancer, 88, pp. 2934-2939
Serafini, A. N., Houston, S. J., Resche, I., Quick, D. P., Grund, F. M., Ell, P. J., Bertrand, A., Harrison, K. A., Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial (1998) Journal of Clinical Oncology, 16 (4), pp. 1574-1581
Sciuto, R., Maini, C. L., Tofani, A., Fiumara, C., Scelsa, M. G., Broccatelli, M., Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89 (1996) Nuclear Medicine Communications, 17 (9), pp. 799-804
Ron, I. -G., Stav, O., Vishne, T., Evan-Sapir, E., Soyfer, V., Agai, R., Cherny, N., Kovner, F., The correlation between palliation of bone pain by intravenous strontium-89 and external beam radiation to linked field in patients with osteoblastic bone metastases (2004) American Journal of Clinical Oncology: Cancer Clinical Trials, 27 (5), pp. 500-504. , DOI 10. 1097/01. coc. 0000135378. 67644. ba
Sciuto, R., Festa, A., Rea, S., Pasqualoni, R., Bergomi, S., Petrilli, G., Maini, C. L., Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial (2002) Journal of Nuclear Medicine, 43 (1), pp. 79-86
Storto, G., Klain, M., Paone, G., Liuzzi, R., Molino, L., Marinelli, A., Soricelli, A., Salvatore, M., Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (2006) Bone, 39 (1), pp. 35-41. , DOI 10. 1016/j. bone. 2005. 12. 004, PII S8756328205005351
Hess, G., Barlev, A., Chung, K., Hill, J. W., Fonseca, E., Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer (2012) Radiat Oncol, 7, p. 168
Collins, C., Eary, J. F., Donaldson, G., Vernon, C., Bush, N. E., Petersdorf, S., Livingston, R. B., Appelbaum, F. R., Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial (1993) Journal of Nuclear Medicine, 34 (11), pp. 1839-1844
Pandit-Taskar, N., Batraki, M., Divgi, C. R., Radiopharmaceutical therapy for palliation of bone pain from osseous metastases (2004) Journal of Nuclear Medicine, 45 (8), pp. 1358-1365. , http: //jnm. snmjournals. org/cgi/reprint/45/8/1358
Mincey, B. A., Perez, E. A., Advances in screening, diagnosis, and treatment of breast cancer (2004) Mayo Clinic Proceedings, 79 (6), pp. 810-816
Decroisette, C., Galerneau, L. M., Hominal, S., Chouaid, C., Epidemiology, management and cost of bone metastases from lung cancer (2013) Rev Mal Respir, 30, pp. 309-315
Zhang, H., Tian, M., Li, S., Liu, J., Tanada, S., Endo, K., Rhenium-188-HEDP Therapy for the Palliation of Pain Due to Osseous Metastases in Lung Cancer Patients (2003) Cancer Biotherapy and Radiopharmaceuticals, 18 (5), pp. 719-726
Reich, C. D., Advances in the treatment of bone metastases (2003) Clin J Oncol Nurs, 7, pp. 641-646
Coronado, M., Redondo, A., Coya, J., Espinosa, E., Couto, R. Ma., Zamora, P., Marin, M. D., Curto, L. M. M., Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease (2006) Clinical Nuclear Medicine, 31 (10), pp. 605-610. , DOI 10. 1097/01. rlu. 0000238304. 08812. c1, PII 0000307220061000000004
Serafini, A. N., Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis (2001) Q J Nucl Med, 45, pp. 91-99
Berger, M., Grignani, G., Giostra, A., Ferrari, S., Ferraresi, V., Tamburini, A., Cefalo, G., Fagioli, F., 153 samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients (2012) Ann Oncol, 23, pp. 1899-1905
Lewington, V. J., Bone-seeking radionuclides for therapy (2005) J Nucl Med, 46, pp. 38S-47S
Turner, J. H., Claringbold, P. G., A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate (1991) Eur J Cancer, 27, pp. 1085-1086
Storto, G., Gallicchio, R., Pellegrino, T., Nardelli, A., De Luca, S., Capacchione, D., Sirignano, C., Pace, L., Impact of 18F-Fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (2013) Nucl Med Biol, 40, pp. 518-523
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Bonomi, P., The functional assessment of cancer therapy scale: Development and validation of the general measure (1993) Journal of Clinical Oncology, 11 (3), pp. 570-579
Hwang, S. S., Chang, V. T., Kasimis, B., Dynamic cancer pain management outcomes: The relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time (2002) Journal of Pain and Symptom Management, 23 (3), pp. 190-200. , DOI 10. 1016/S0885-3924 (01) 00418-3, PII S0885392401004183
Storto, G., Radionuclide Therapy (2009) Bone Metastases: A Translational and Clinical Approach, 12, pp. 321-341. , Kardamakis D, Vassiliou V, Chow E (eds) Springer, Netherlands
Sartor, O., Overview of samarium Sm 153 lexidronam in the treatment of painful metastatic bone disease (2004) Rev Urol, 6, pp. S3-S12
Reddi, A.H., Roodman, D., Freeman, C., Mohla, S., Mechanisms of tumor metastasis to the bone: Challenges and opportunities (2003) J Bone Miner Res, 18, pp. 190-194
Nielsen, O.S., Munro, A.J., Tannock, I.F., Bone metastases: Pathophysiology and management policy (1991) J Clin Oncol, 9, pp. 509-524
Coleman, R.E., Rubens, R.D., The clinical course of bone metastases from breast cancer (1987) British Journal of Cancer, 55 (1), pp. 61-66
Keller, E.T., Brown, J., Prostate cancer bone metastases promote both osteolytic and osteoblastic activity (2004) J Cell Biol, 91, pp. 718-729
Hortobagyi, G.N., Novel approaches to the management of bone metastases in patients with breast cancer (2002) Semin Oncol, 29, pp. 134-144
Burris III, H.A., Lebrun, F., Rugo, H.S., Beck, J.T., Piccart, M., Neven, P., Baselga, J., Noguchi, S., Healthrelated quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial (2013) Cancer, 119, pp. 1908-1915
Perry, C.M., Figgitt, D.P., Zoledronic acid: A review of its use in patients with advanced cancer (2004) Drugs, 64 (11), pp. 1197-1211. , DOI 10.2165/00003495-200464110-00004
Soloway, M.S., Ishikawa, S., Van Der, Z.R., Todd, B., Prognostic factors in patients with advanced prostate cancer (1989) Urology, 33 (5 SUPPL.), pp. 53-56. , DOI 10.1016/0090-4295(89)90107-6
Kassamali, R.H., Ganeshan, A., Hoey, E.T., Crowe, P.M., Douis, H., Henderson, J., Pain management in spinal metastases: The role of percutaneous vertebral augmentation (2011) Ann Oncol, 22, pp. 782-786
Body, J.J., Bone metastases and tumor-induced hypercalcaemia (1992) Curr Opin Oncol, 4, pp. 624-631
Serafini, A.N., Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastasis (2000) Cancer, 88, pp. 2934-2939
Serafini, A.N., Houston, S.J., Resche, I., Quick, D.P., Grund, F.M., Ell, P.J., Bertrand, A., Harrison, K.A., Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial (1998) Journal of Clinical Oncology, 16 (4), pp. 1574-1581
Ron, I.-G., Stav, O., Vishne, T., Evan-Sapir, E., Soyfer, V., Agai, R., Cherny, N., Kovner, F., The correlation between palliation of bone pain by intravenous strontium-89 and external beam radiation to linked field in patients with osteoblastic bone metastases (2004) American Journal of Clinical Oncology: Cancer Clinical Trials, 27 (5), pp. 500-504. , DOI 10.1097/01.coc.0000135378.67644.ba
Mincey, B.A., Perez, E.A., Advances in screening, diagnosis, and treatment of breast cancer (2004) Mayo Clinic Proceedings, 79 (6), pp. 810-816
Reich, C.D., Advances in the treatment of bone metastases (2003) Clin J Oncol Nurs, 7, pp. 641-646
Serafini, A.N., Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis (2001) Q J Nucl Med, 45, pp. 91-99
Lewington, V.J., Bone-seeking radionuclides for therapy (2005) J Nucl Med, 46, pp. 38S-47S
Turner, J.H., Claringbold, P.G., A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate (1991) Eur J Cancer, 27, pp. 1085-1086
Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Bonomi, P., The functional assessment of cancer therapy scale: Development and validation of the general measure (1993) Journal of Clinical Oncology, 11 (3), pp. 570-579
Hwang, S.S., Chang, V.T., Kasimis, B., Dynamic cancer pain management outcomes: The relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time (2002) Journal of Pain and Symptom Management, 23 (3), pp. 190-200. , DOI 10.1016/S0885-3924(01)00418-3, PII S0885392401004183
Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain
We evaluated the pain response and daily discomfort in patients suffering from a borderline degree of bone pain due to breast or lung cancer bone metastases, who had undergone early palliative radionuclide treatment. The results were compared with those from patients who had received standard analgesic therapy. Twenty-one patients (65.7 ± 3 years; 17 women) with metastatic bone cancer underwent samarium-153 (Sm-153) ethylene diamine tetramethylene phosphonate (EDTMP) administration (group A) and 18 patients (64.3 ± 8 years; 16 women) continued to receive standard analgesics (group B; control group). The patients kept a daily pain diary assessing both their discomfort and the pain at specific sites by means of a visual analog scale, rating from 0 (no discomfort-no pain) to 10 (worst discomfort-pain). These diaries were reviewed weekly for 2 months and three physicians rated the pain response on a scale from -2 (considerable deterioration) to +2 (considerable improvement). Baseline characteristics were similar in both groups. The reduction of total discomfort and of bone pain in group A was significantly greater compared to group B (p < 0.0001). A significant improvement of clinical conditions was observed in group A, where the physician rate changed from -1 to 1, compared to group B in which the rate changed from -1 to 0. Sm-153 EDTMP therapy can be considered for patients with bone pain from breast and lung cancer in advance, i.e., before the establishment of severe pain syndrome. © 2013 The Japanese Society for Bone and Mineral Research and Springer.
We evaluated the pain response and daily discomfort in patients suffering from a borderline degree of bone pain due to breast or lung cancer bone metastases, who had undergone early palliative radionuclide treatment. The results were compared with those from patients who had received standard analgesic therapy. Twenty-one patients (65.7 ± 3 years; 17 women) with metastatic bone cancer underwent samarium-153 (Sm-153) ethylene diamine tetramethylene phosphonate (EDTMP) administration (group A) and 18 patients (64.3 ± 8 years; 16 women) continued to receive standard analgesics (group B; control group). The patients kept a daily pain diary assessing both their discomfort and the pain at specific sites by means of a visual analog scale, rating from 0 (no discomfort-no pain) to 10 (worst discomfort-pain). These diaries were reviewed weekly for 2 months and three physicians rated the pain response on a scale from -2 (considerable deterioration) to +2 (considerable improvement). Baseline characteristics were similar in both groups. The reduction of total discomfort and of bone pain in group A was significantly greater compared to group B (p < 0.0001). A significant improvement of clinical conditions was observed in group A, where the physician rate changed from -1 to 1, compared to group B in which the rate changed from -1 to 0. Sm-153 EDTMP therapy can be considered for patients with bone pain from breast and lung cancer in advance, i.e., before the establishment of severe pain syndrome. © 2013 The Japanese Society for Bone and Mineral Research and Springer.
Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain
| ▼ Animal Care, interventional procedures, anesthesia and analgesia of murine models in preclinical imaging |
Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain
Other filter: ([btitle,keywords] "Low Degree Bone Pain ...
Gallicchio R, Scapicchio D, Nardelli A, Pellegrino T, Prisco M, Mainenti P, Sirignano C, Pedicini P, Storto G
* Assessment of residual radioactivity by a comprehensive wireless, wearable device in thyroid cancer patients undergoing radionuclide therapy and comparison with the results of a home device: a feasibility study (46 views) (PDF 17 views)
Ieee J Transl Eng Health Med (ISSN: 2168-2372linking), 2020 Dec 2; 9: 2700306-2700306.
Impact Factor: 2.53
View Export to BibTeX Export to EndNote
Altug C, Gunes H, Nocentini A, Monti SM, Buonanno M, Supuran CT
* Synthesis of isoxazole-containing sulfonamides with potent carbonic anhydrase II and VII inhibitory properties (301 views)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391, 0968-0896linking), 2017 Feb 15; 25(4): 1456-1464.
Impact Factor: 2.881
View Export to BibTeX Export to EndNote
D'Antuono F, Nardelli A, Gallicchio R, Giacomobono S, Venetucci A, Pellegrino T, Leggiadro F, D'Errico N, Gattozzi D, Mainenti PP, Storto G
* Palliative Treatment of Bone Metastases with Sm-153 EDTMP at Pain Onset (287 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (346 views) (PDF 10 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
View Export to BibTeX Export to EndNote
Cirillo G, Colangelo AM, Bianco MR, Cavaliere C, Zaccaro L, Sarmientos P, Alberghina L, Papa M
* BB14, a Nerve Growth Factor (NGF)-like peptide shown to be effective in reducing reactive astrogliosis and restoring synaptic homeostasis in a rat model of peripheral nerve injury (402 views)
Biotechnology Advances (ISSN: 0734-9750), 2012 Jan; 30(1): 223-232.
Impact Factor: 9.599
View Export to BibTeX Export to EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (468 views)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
View Export to BibTeX Export to EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (260 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Storto G, Pellegrino T, Nardelli A, De Falco T, Castaldi E, Ortosecco G, Capasso E, Erra P, Speranza A, Klain M, Molino L, Di Nuzzo C, Pace L, Salvatore M
* Impact of PET-CT with F-18 Fluoride in Implementing Treatment of Painful Bone Metastases with Sm-153 EDTMP (288 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT
* Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II 'selective' inhibitor celecoxib (323 views)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2006 Jan 15; 16(2): 437-442.
Impact Factor: 2.538
View Export to BibTeX Export to EndNote
Storto G, Speranza A, Pellegrino T, Panico M, Cella L, Nardelli A, Russo AA, Klain M, Soricelli A, Pace L, Salvatore M
* Activity Threshold Determining Cumulative Aderse-Effects In Patients Undergoing Peptide Receptor Radionuclide Therapy With Y-90 Octreotate (290 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006; 33: 338-338.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Tauchmanova L, De Rosa G, Serio B, Fazioli F, Mainolfi C, Lombardi G, Colao A, Salvatore M, Rotoli B, Selleri C
* Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: A single center experience and a review (277 views)
Cancer (ISSN: 0008-543x), 2003 May 15; 97(10): 2453-2461.
Impact Factor: 2.045
View Export to BibTeX Export to EndNote
Romano M, Giojelli A, Tamburrini O, Salvatore M
* Chemoembolization for hepatocellular carcinoma: Effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization (424 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2003 Apr; 105(4): 350-355.
Impact Factor: 1.368
View Export to BibTeX Export to EndNote
* Assessment of residual radioactivity by a comprehensive wireless, wearable device in thyroid cancer patients undergoing radionuclide therapy and comparison with the results of a home device: a feasibility study (46 views) (PDF 17 views)
Ieee J Transl Eng Health Med (ISSN: 2168-2372linking), 2020 Dec 2; 9: 2700306-2700306.
Impact Factor: 2.53
View Export to BibTeX Export to EndNote
Altug C, Gunes H, Nocentini A, Monti SM, Buonanno M, Supuran CT
* Synthesis of isoxazole-containing sulfonamides with potent carbonic anhydrase II and VII inhibitory properties (301 views)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391, 0968-0896linking), 2017 Feb 15; 25(4): 1456-1464.
Impact Factor: 2.881
View Export to BibTeX Export to EndNote
D'Antuono F, Nardelli A, Gallicchio R, Giacomobono S, Venetucci A, Pellegrino T, Leggiadro F, D'Errico N, Gattozzi D, Mainenti PP, Storto G
* Palliative Treatment of Bone Metastases with Sm-153 EDTMP at Pain Onset (287 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (346 views) (PDF 10 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
View Export to BibTeX Export to EndNote
Cirillo G, Colangelo AM, Bianco MR, Cavaliere C, Zaccaro L, Sarmientos P, Alberghina L, Papa M
* BB14, a Nerve Growth Factor (NGF)-like peptide shown to be effective in reducing reactive astrogliosis and restoring synaptic homeostasis in a rat model of peripheral nerve injury (402 views)
Biotechnology Advances (ISSN: 0734-9750), 2012 Jan; 30(1): 223-232.
Impact Factor: 9.599
View Export to BibTeX Export to EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (468 views)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
View Export to BibTeX Export to EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (260 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Storto G, Pellegrino T, Nardelli A, De Falco T, Castaldi E, Ortosecco G, Capasso E, Erra P, Speranza A, Klain M, Molino L, Di Nuzzo C, Pace L, Salvatore M
* Impact of PET-CT with F-18 Fluoride in Implementing Treatment of Painful Bone Metastases with Sm-153 EDTMP (288 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT
* Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II 'selective' inhibitor celecoxib (323 views)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2006 Jan 15; 16(2): 437-442.
Impact Factor: 2.538
View Export to BibTeX Export to EndNote
Storto G, Speranza A, Pellegrino T, Panico M, Cella L, Nardelli A, Russo AA, Klain M, Soricelli A, Pace L, Salvatore M
* Activity Threshold Determining Cumulative Aderse-Effects In Patients Undergoing Peptide Receptor Radionuclide Therapy With Y-90 Octreotate (290 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006; 33: 338-338.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Tauchmanova L, De Rosa G, Serio B, Fazioli F, Mainolfi C, Lombardi G, Colao A, Salvatore M, Rotoli B, Selleri C
* Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: A single center experience and a review (277 views)
Cancer (ISSN: 0008-543x), 2003 May 15; 97(10): 2453-2461.
Impact Factor: 2.045
View Export to BibTeX Export to EndNote
Romano M, Giojelli A, Tamburrini O, Salvatore M
* Chemoembolization for hepatocellular carcinoma: Effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization (424 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2003 Apr; 105(4): 350-355.
Impact Factor: 1.368
View Export to BibTeX Export to EndNote
12 Records (7 excluding Abstracts).
Total impact factor: 42.863 (22.133 excluding Abstracts).
Total 5 year impact factor: 46.489 (25.325 excluding Abstracts).
Total impact factor: 42.863 (22.133 excluding Abstracts).
Total 5 year impact factor: 46.489 (25.325 excluding Abstracts).
396 views. Last view on Saturday 01 April 2023, 11:14:42
ibb.cnr.it
